Research Summaries

Tanning Peptides: MT-1, MT-2, and the Melanocortin System

PepTracker Pro Research Team January 20, 2026 14 min read

Last reviewed: April 17, 2026

The Melanocortin System
Melanin Biology and Photoprotection
MC1R Polymorphisms and Genetic Variation
MT-1 (Melanotan I / Afamelanotide)
EPP Clinical Trial Data
MT-2 (Melanotan II)
The PT-141 Connection: From MT-2 to FDA Approval
Mole Monitoring and Melanoma Risk
MT-2 Side Effects Deep Dive
Regulatory Enforcement and Legal Status
Who Studies These and Why
Comparing MT-1, MT-2, and PT-141
Important Medical Guidance

The Melanocortin System

The melanocortin system is a group of five G-protein-coupled receptors (MC1R through MC5R) and their natural ligands, the melanocortins (peptides including alpha-melanocyte-stimulating hormone and corticotropin-related peptides). These receptors regulate multiple physiological processes: MC1R mediates skin pigmentation and melanin production; MC3R and MC4R regulate energy balance and appetite; MC4R affects blood pressure and cardiovascular function. Alpha-melanocyte-stimulating hormone (α-MSH) is the primary endogenous ligand, derived from the precursor hormone pro-opiomelanocortin (POMC). Synthetic melanocortin analogs form the basis of tanning peptide research. Understanding the biology of all melanocortin receptors is critical for predicting both desired effects and side effects of melanocortin peptides.

Melanin Biology and Photoprotection

Melanin is a pigment produced by melanocytes (specialized skin cells) that absorbs ultraviolet radiation and dissipates it as heat, protecting DNA from UV-induced mutations that cause skin cancer. Melanin synthesis is regulated by α-MSH binding to MC1R on melanocyte surfaces, which triggers a cAMP-mediated signaling cascade. Increased cAMP activates MITF (microphthalmia-associated transcription factor), which upregulates tyrosinase (the rate-limiting enzyme in melanin synthesis). Individuals with more efficient melanin production (darker skin, high MC1R activity) have lower skin cancer risk from UV exposure. Synthetic α-MSH analogs amplify this normal pathway, increasing melanin production systemically without UV exposure. Theoretically, this provides photoprotection without sunburn or UV-related aging.

MC1R Polymorphisms and Genetic Variation

MC1R gene variants significantly affect melanin production and tanning response. Certain variants (especially in individuals of red-hair phenotype) produce less responsive MC1R, resulting in lighter skin and reduced tanning capacity. These same individuals have higher skin cancer risk. Melanocortin peptide efficacy varies by MC1R genotype — some people are 'genetic responders' who darken dramatically with α-MSH analogs, others show minimal response. This genetic heterogeneity is not routinely tested and explains why tanning peptide results vary so dramatically between individuals. Family history of tanning capacity is a predictor of melanocortin peptide response.

MT-1 (Melanotan I / Afamelanotide)

MT-1, also known as afamelanotide (Scenesse in Europe), is a 13-amino acid linear analog of α-MSH with an additional N-terminal amino acid. It selectively targets MC1R with minimal cross-reactivity to other melanocortin receptors. This selectivity is advantageous: it reduces off-target effects on appetite, blood pressure, and sexual function. Afamelanotide is FDA-approved in Europe (under the brand name Scenesse) for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme sun sensitivity and painful photosensitivity reactions. In EPP patients, afamelanotide increases melanin production, providing photoprotection that allows safe sun exposure. Clinical trials showed approximately 60-70% reduction in phototoxic reactions in EPP patients treated with afamelanotide compared to placebo.

EPP Clinical Trial Data

The pivotal Phase 3 RAPID trial enrolled 89 EPP patients and showed that afamelanotide significantly reduced the number of painful phototoxic reactions (primary endpoint achieved). Secondary endpoints included increased melanin content (measured by reflectance spectrophotometry) and improved quality of life. Afamelanotide is administered as a subcutaneous implant (16 mg, replaced every 2 months), releasing peptide gradually. The approval was based on this substantial clinical benefit in a serious rare disease. EPP is indeed rare (1:50,000 to 1:200,000 incidence), limiting the drug's market size but justifying FDA orphan drug designation and European approval.

MT-2 (Melanotan II)

MT-2 is a cyclic 7-amino acid peptide (cyclized through peptide bond formation between first and last residues). This cyclization and amino acid substitutions create a super-agonist structure that activates multiple melanocortin receptors with high affinity. MT-2 is not selective like MT-1 — it activates MC1R (pigmentation), MC3R/MC4R (appetite, energy balance), and MC5R-mediated sebaceous gland function. This non-selectivity produces effects beyond tanning: spontaneous penile erections (even in women, affecting clitoral tissue), nausea, facial flushing, elevated blood pressure, appetite suppression, and libido changes. Some users report MT-2 effects as desirable; others find them problematic. The mechanism of erections appears to be through MC3R/MC4R activation in spinal circuits that control erectile function.

The PT-141 Connection: From MT-2 to FDA Approval

When researchers noticed MT-2's potent effects on sexual arousal, they engineered PT-141 (bremelanotide) — a truncated melanocortin analog — to selectively target the pathways responsible for sexual function while minimizing pigmentation effects. PT-141 was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, becoming one of the few melanocortin-derived drugs to achieve full regulatory approval. PT-141 is administered as a subcutaneous injection before sexual activity (boosts effect within 15-30 minutes, duration ~2 hours). Clinical trials showed modest improvement in sexual desire and satisfaction in HSDD women. PT-141 carries risks of elevated blood pressure, nausea, and unwanted changes in melanin (darkening of existing moles or development of new moles).

Mole Monitoring and Melanoma Risk

A major concern with melanocortin peptides is potential stimulation of existing moles or development of new nevi (moles). In clinical trials of afamelanotide, new moles developed in approximately 20-30% of users. Existing moles often darkened. This is mechanistically expected (melanin production increases), but the clinical significance is unclear: are darkened moles benign or do they indicate malignant transformation risk? Current guidance is that anyone using melanocortin peptides should: (1) undergo baseline dermoscopy (detailed mole evaluation by dermatologist), (2) have moles photographed for comparison, (3) have periodic dermatological surveillance, (4) avoid using melanocortin peptides if they have numerous atypical nevi or personal/family history of melanoma. For high-risk individuals, the theoretical melanoma risk may outweigh cosmetic benefits.

MT-2 Side Effects Deep Dive

Beyond nausea and blood pressure elevation, MT-2 can cause: facial flushing and redness (persistent), suppressed appetite (sometimes severe), libido changes, spontaneous erections (in both males and females), darkening of existing moles, development of new moles, increased freckles, changes in existing tattoo appearance (via melanin deposition), and in some cases, reports of personality changes or mood alterations (mechanism unclear — possibly indirect through appetite/energy pathways). Side effects vary dramatically between individuals and doses. Some users tolerate MT-2 well; others experience severe nausea or other effects within hours of injection. Dose escalation protocols (starting low, increasing gradually) help assess individual tolerance.

Regulatory Enforcement and Legal Status

MT-2 is not approved by the FDA or most national regulatory agencies. It remains widely sold through unregulated online sources despite lacking regulatory authorization. The DEA and FDA have issued enforcement actions against some suppliers. In many countries, MT-2 is sold as a 'research chemical' — a gray-market designation meaning it's sold 'for research only' but is widely used for non-research purposes. This regulatory ambiguity creates risks: variable quality, contamination potential, lack of medical oversight, legal jeopardy in some jurisdictions. MT-1 (afamelanotide) is regulated in Europe for EPP but is not available in the US except through compassionate use programs. PT-141 is FDA-approved but prescription-only.

Who Studies These and Why

MT-1 research centers on dermatology groups working on EPP and other photosensitivity disorders. PT-141 research involves sexual medicine specialists and pharmaceutical companies interested in HSDD treatment. MT-2 research is mostly limited to unaffiliated, independent researchers in research communities — it has not been pursued by pharmaceutical companies for obvious reasons (liability, regulatory hurdles, reputational concerns). Published scientific literature on MT-2 is sparse (mostly from the 1980s-1990s); most current MT-2 data comes from user reports rather than controlled studies.

Comparing MT-1, MT-2, and PT-141

MT-1: Selective, lower side effect profile, regulated approval (EPP), slow-acting implant, limited pigmentation studies in non-EPP populations. MT-2: Non-selective, multiple effects beyond pigmentation, unregulated, more rapid action (injection), substantial off-label use despite lack of approval. PT-141: Selective for sexual function, FDA-approved, injection, minimal intended pigmentation effect but mole risk remains. For cosmetic tanning specifically, MT-1 is safest but approval is limited to EPP. MT-2 produces tanning but with multi-system effects. Neither should be considered a casual cosmetic tool.

Important Medical Guidance

Anyone considering melanocortin peptides should: (1) consult a dermatologist before use, (2) undergo baseline skin evaluation including mole documentation, (3) understand the mole/melanoma risk (even if small, it's real and incompletely understood), (4) avoid use if high-risk for melanoma, (5) maintain regular dermatological surveillance if using, (6) understand that regulatory approval (or lack thereof) reflects actual safety/efficacy data, (7) prioritize UV protection and sun avoidance when possible instead of relying on peptide-induced tanning. PT-141 for HSDD should only be used under physician supervision with appropriate cardiovascular monitoring.

Ready to track your peptide research?

Open PepTracker Pro

PepTracker Pro Research Team

The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.

Citations

[1] Langendonk JG et al. — Afamelanotide for EPP, N Engl J Med 2015 Source
[2] Dorr RT et al. — Effects of a superpotent melanotropic peptide, Life Sci 1996 Source
[3] Böhm M et al. — Afamelanotide for the prevention of acute UV photosensitivity reactions, J Am Acad Dermatol 2010 Source
[4] Diamond-Stanic MK et al. — Melanocortin-4 receptor activation promotes vascular function and reduces blood pressure, Hypertension 2012 Source

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer →